Purpose: Eslicarbazepine-acetate (ESL) is a third generation antiepileptic drug licensed as adjunctive therapy in adults with focal seizures. Efficacy and safety of ESL have been established in real-life setting. However, data about outcomes in elderly patients are scarce. Primary endpoint was to evaluate outcomes of ESL in elderly patients. Method: This was a retrospective survey that included patients >65 years with focal seizures who started ESL between January 2010 and July 2012 at 12 Spanish Hospitals. ESL was prescribed individually according to real-life practice. Efficacy and safety were evaluated over 1 year. These patients were included within the bigger study ESLIBASE. Results: We included 29 patients, most of them males (18). Mean age was 71.2 year-old and epilepsy evolution was 20 years. Eighteen were pharmacorresistant at baseline. At 12 months, the mean dose was 850 mg/day, the retention rate 69%, the responder rate 62% and 24.1% were seizure-free. At 12 months, 16 patients (55.2%) had 1 adverse effect (AE), that led to discontinuation in 7 patients. Dizziness, nausea and ataxia were the most common AEs. The tolerability profile improved in 4/5 patients who switched from carbamazepine (CBZ) or oxcarbazepine (OXC) to ESL due to AEs. Conclusions: ESL was well-tolerated and effective in elderly patients in a real-life setting over 1 year, with a dose around 800 mg/day. AE effects improved in most of who switched from CBZ or OXC to ESL
INTRODUCTION
Epilepsy is a disease of the brain defined by: a) two unprovoked seizures occurring >24 hours apart; b) one unprovoked seizure and a probability of 60% of further seizures over the next 10 years; and c) diagnosis of an epilepsy syndrome [1] . The most frequent causes in elderly patients are vascular and dementia [2] .
Nutritional status, co-morbidities and concomitant medications influence in antiepileptic drugs (AEDs) pharmacokinetics, with variable response and tolerability in older people [3] . They are frequently excluded from clinical trials of new AEDs. Therefore, data from those studies are far from the real-life setting in this population. This scenario highlights the role of real-life studies of AEDs in elderly.
Eslicarbazepine-acetate (ESL) is a third generation carboxamide, as carbamazepine (CBZ) and oxcarbazepine (OXC). OXC and ESL originate S-licarbazepine (active metabolite) and R-licarbazepine (inactive metabolite), OXC in 4:1 proportion and ESL in 20:1 proportion; none of them originates 10,11-epoxide, related with adverse events (AEs) of CBZ [4] . ESL is a sodium channel blocker (SCB), with low affinity in the resting state and a selective interference with voltage-gated sodium channel slow inactivation states [5] . ESL was licensed as adjunctive therapy for focal seizures after several clinical trials [6] [7] [8] .
There is scarce information about ESL in elderly patients. One real-life study with ESL as add-on treatment to antiepileptic monotherapy in patients >60 years with 6-months period showed a retention rate of 78% [9] . ESLIBASE was a Spanish multicenter study that established efficacy and safety of ESL in a real-life setting [10] . The aim of this study is to analyze efficacy and tolerability of ESL in elderly patients included within ESLIBASE study.
METHODS
We analyzed retrospectively the efficacy and tolerability of ESL in patients >65 year-old included within ESLIBASE study. Timepoints were the baseline visit (when ESL was added), 3, 6 and 12 months visits. At each visit, number of seizures, AEs and changes on other AEDs were noted. All patients had at least one blood test, including sodium, over the follow-up. Number of seizures per month was the mean of the previous 3 months at baseline visit. Concomitant AED were grouped by mechanism of action: 1) SCB drugs included immediate-release CBZ, immediate-release OXC, phenytoin (PHT), lamotrigine (LTG) and lacosamide (LCM); 2) non-SCB drugs.
Primary endpoint was to assess the efficacy of ESL over a 12 months period. Retention rate regarded to patients still taking ESL at 12 months. Responder rate was defined as subjects with a seizure number reduction 50% compared to baseline. Secondary objective was to evaluate the tolerability. Eventually, efficacy and tolerability was analyzed in those patients who switched from CBZ or OXC to ESL.
Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS) version 16.0; p values of 0.05, meaning that alfa error was less than 5%, were regarded as significant. We performed the intention-to-treat analysis using the last observation carried forward procedure to account for missed data.
RESULTS

Baseline characteristics
At baseline visit, we included 29 patients. Main characteristics are summarized in Table 1 .
The reason for starting with ESL was lack of efficacy in 24 patients and AEs in 5. At 3, 6 and 12 months, mean dose was 770, 840 and 850 mg/day (range 400-1600 mg/day). The dose of 800 mg was the most frequent at every time-point. Drop-out rate was 20.7% at 3 months (6 patients), 24.1% at 6 months (7 patients) and 31% (9 patients) at 12 months; therefore the 1-year retention rate was 69% (20 patients). Four patients discontinued it due to a combination of AEs and inefficacy (all within the first 3 months), 3 for AEs only and 2 because of inefficacy.
Regarding to concomitant AEDs, 11 patients were taking one at baseline, 10 were taking two, 5 were taking three and 4 were taking four. One year later, 4 patients were not taking any AED, 12 were taking one, 10 were two, 1 was taking three and 2 were taking four. Twenty-five patients had refractory epilepsy (86,2%) and six patients suffered secondary generalized seizures.
Additionally, 18 patients had a concomitant SCB drug and 11 were taking non-SCB. Levetiracetam (LEV) was the most used AED (20 patients).
Efficacy
At 12 months, the responder rate was 62%; 24.1% of patients attained seizure freedom (Fig. 1) . Focused on the 25 pharmacorresistant patients (those who had tried at least 2 AEDs before), the responder rate was 58.4%, and 16.7% were seizure-free. Among patients taking SCB drugs, the responder rate was 50% (16.7% seizure-free); in contrast, this rate rose up to 81.9% in those on non-SCB drugs (36.4% seizure-free). 
Tolerability
AEs were reported by 34.5% of patients at 3 months, 48.3% at 6 months and 55.2% at 12 month, leading to treatment discontinuation in 24.1% (7 patients). Dizziness and ataxia were the most common AEs (4 patients each one); additionally, 3 described hyponatremia, 3 somnolence, 2 bradypsychia, 2 periictal psychosis, and 1 skin rash, 1 diplopia, 1 headache and 1 status epilepticus. All treatment withdrawals at 3 and 6 months were due to AEs, as well as 7/9 at 12 months. No deaths were reported.
AEs were higher in patients taking SCB drugs than in those who were on non-SCB drugs (61.1% versus 45.4% at 12 months). Regarding patients who discontinued ESL due to AEs, 27.8% were taking SCB drugs and 18.2% non-SCB drugs. Interestingly, 6/7 patients taking 1200 mg/day and 2/2 achieving 1600 mg/day had AEs; the two later discontinued ESL for this reason.
Switching from CBZ or OXC to ESL
Five patients were switched from CBZ or OXC due to AE (3 from CBZ and 2 from OXC). The tolerability profile improved in 4/5 patients (all from CBZ and 1 from OXC).
DISCUSSION
Elderly population has therapeutic particularities that we should keep in mind when prescribing AEDs. Gut absorption, changes in lipid and water distribution volumes, reduction of plasma protein binding, decrease in metabolism and clearance and drug interactions influence in efficacy and tolerability of any drug. These factors make this population heterogeneous and, therefore, the response varies widely.
The results of this real-life setting over 1-year in patients older than 65 years-old demonstrated that ESL is also effective and welltolerated in this population subgroup. Compared with younger patients (<65 years), ESL had better efficacy (62% vs 48.8%), more side effects (55.2% vs 36.9%) and slightly lower retention rate (69% vs 72.8%). Additionally, the mean daily dose at the end of the follow-up was also lower (850 mg/day vs 1032.6 mg/day).
One interesting point is that efficacy is better in elderly patients though the achieved dose is lower. Two reasons could be the etiology of epilepsy (cryptogenic or vascular in half of patients, with a good prognosis) and decreased ESL metabolism and clearance. This finding is in agreement with previous studies that highlighted a favorable outcome with lower AED doses in elderly [3] .
Older people are more prone to develop AE with AED. Our data showed that ESL is not an exception. Roughly half of the patients complained about any AE, mainly dizziness and ataxia, similar to the whole ESLIBASE group [10] , and around 25% had to stop it. This increase in AE prevalence probably leads to the slight decrease in retention rate similar than in the real-life study with ESL in elderly conducted by Karlsson [9] . Interestingly, early drop-out were more prevalent than late drop-outs and all of them were due to AE; this phenomenon highlights that severe AE show up early in elderly patients. Three patients had hyponatremia, but only one developed symptoms (confusion) that resolved after withdrawal of ESL. The reason of low rate of hyponatremia may be the low dose of ESL they were taking. A recent study in 32 patients with post-stroke epilepsy treated with ESL found hyponatremia in 4 patients (only one was > 65 years) [11] . Therefore, a serum sodium monitoring is recommended in these patients.
As in ESLIBASE, patients taking ESL combined with non-SCB AED had better efficacy and tolerability [10] . In our series, the only non-SCB drug that patients were taken was LEV, meaning that ESL could be a good combination in elderly patients who are not well controlled with LEV in monotherapy. Finally, 80% of patients who switched from CBZ or OXC to ESL due to AE developed an improvement in tolerability. This was also demonstrated in other studies [12] . It seems that elderly patients follow the same trend, although the number of patients is scarce.
In summary, ESL was effective and well-tolerated in elderly patients in a real-life setting over 1 year, with a dose around 800 mg/day. AEs improved in most of patients who switched from CBZ or OXC to ESL.
